Oncology News

Oncology
sponsor

Your Article Summary

See Latest Articles
(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature
Leukemia Research, 06/19/09

Guastafierro S et al. - The authors report the case of a 20-years-old male patient in chronic phase CML who maintained undetectable BCR/ABL mRNA levels, despite IM discontinuation over a period of 15 months after achieving CMR.

Related Articles

Daunorubicin Versus Mitoxantrone Versus Idarubicin as Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10
Journal of Clinical Oncology, 10/23/09    Relevance Score: 91%

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives
Current Opinion in Oncology, 10/14/09    Relevance Score: 90%

Genetic lesions in chronic lymphocytic leukemia: clinical implications
Current Opinion in Oncology, 10/14/09    Relevance Score: 89%

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP
Blood, 10/09/09    Relevance Score: 89%

Minor histocompatibility antigens-targets of graft versus leukemia responses
International Journal of Hematology, 10/07/09    Relevance Score: 89%

Today in Leukemia/Lymphoma...keeping you current

Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkins lymphomas
American Journal of Hematology, 12/06/09

Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006
European Journal of Haematology, 12/06/09

SNP array analysis of tyrosine kinase inhibitor (TKI) resistant chronic myeloid leukemia (CML) identifies heterogeneous secondary genomic alterations
Blood, 12/06/09

 See all of Leukemia/Lymphoma

Today in Myeloproliferative Dz...keeping you current

Pulmonary Alveolar Proteinosis as a Terminal Complication in a Case of Myelodysplastic Syndrome with idic(20q-)
Acta Haematologica, 12/04/09

Environmental-mediated drug resistance: a target for multiple myeloma therapy
Expert Review of Hematology, 12/02/09

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission
Hematology, 12/02/09

 See all of Myeloproliferative Dz